ArticleCell host & microbe2019
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Open access · bronzeAbstract read
In one paragraph
Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Underinvestment in diagnostic and vaccine research & development has put the world at greater risk from the Bundibugyo virus epidemic in 2026.Virulence · 2026Article
- Post-exposure prophylaxis with a monoclonal antibody cocktail after Bundibugyo ebolavirus exposure in adults and children.Nature medicine · 2026Article
- A case of Bundibugyo virus disease treated with monoclonal antibodies and remdesivir.Nature medicine · 2026Article
- On the 50th year responding to Ebola: mapping diagnostic, vaccine, and therapeutic gaps across ebolavirus species.MedScience · 2026Review
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.BMC infectious diseases · 2026Article
- Pan-filovirus activity of an IGF2-fused monoclonal antibody: Impairment by IGF1R cross-engagement and rescue via IGF2 Y27L mutation.Virus research · 2026Article
- Bundibugyo virus-perspectives for the current outbreak.Npj viruses · 2026Article
- Recombinant Bombali ebolavirus in cynomolgus macaques as a survival model of Ebola virus disease.Nature communications · 2026Article
- Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivors.Research square · 2026Article
- Article
- Nanobody targeting glycan cap confers broad orthoebolavirus neutralization.Virologica Sinica · 2026Article
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Bispecific antibody engineered from two non-protective antibodies confers full protection against anthrax toxin through inhibition of PA83 cleavage.Microbiology spectrum · 2025Article
- Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus.Nature communications · 2025Article
- Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.Antibodies (Basel, Switzerland) · 2025Review
- Monoclonal Antibody Production Against Filoviruses from Immunized Mice.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Reactive oxygen species-related oxidative changes are associated with splenic lymphocyte depletion in Ebola virus infection.Npj imaging · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 7 institutions in 2 countries.
Zachary A BornholdtMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Andrew S HerbertUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Chad E MireDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Shihua HeSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Robert W CrossDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Anna Z WecDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Dafna M AbelsonMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Joan B GeisbertDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Rebekah M JamesUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Md Niaz RahimSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
Wenjun ZhuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Viktoriya BorisevichDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Logan BanadygaSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Bronwyn M GunnThe Ragon Institute, Cambridge, MA, USA.
Krystle N AgansDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Ariel S WirchnianskiDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Eileen GoodwinAdimab LLC, Lebanon, NH, USA.
Kevin TierneySpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
William S ShestowskyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Ognian BohorovMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Natasha BohorovaMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Jesus VelascoMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Eric AilorMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Do KimMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Michael H PaulyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Kevin J WhaleyMapp Biopharmaceutical, Inc., San Diego, CA, USA.
Galit AlterThe Ragon Institute, Cambridge, MA, USA.
Laura M WalkerAdimab LLC, Lebanon, NH, USA.
Kartik ChandranDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego, CA, USA. Electronic address: larry.zeitlin@mappbio.com.
Xiangguo QiuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada; Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. Electronic address: xiangguo.qiu@canada.ca.
Thomas W GeisbertDepartment of Microbiology and Immunology, Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA. Electronic address: twgeisbe@utmb.edu.
John M DyeUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA. Electronic address: john.m.dye1.civ@mail.mil.
The University of Texas Medical Branch at Galveston · USPublic Health Agency of Canada · CAAlbert Einstein College of Medicine · USUnited States Army Medical Research Institute of Infectious Diseases · USAdimab (United States) · USRagon Institute of MGH, MIT and Harvard · USUniversity of Manitoba · CA
Funding
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6MSupplemental Research Project (SRP)U19AI109711 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2014 to 2018
$26.6MA "Trojan Horse" bispecific antibody strategy for broad filovirus therapeuticsR01AI132256 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK, LAI, JONATHAN R. · 2017 to 2021
$6.1MGeographic Medicine and Emerging InfectionsT32AI070117 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WEISS, LOUIS M. · 2008 to 2023
$5.1MHost-virus interactions in the control of filovirus entryR01AI134824 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK · 2018 to 2021
$1.9MNIAID NIH HHS R01 AI132256NIAID NIH HHS R01 AI134824NIAID NIH HHS T32 AI070117NIAID NIH HHS U19 AI109711NIAID NIH HHS U19 AI109762
Abstract
Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134
Indexed as
AnimalsAnimal WelfareAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCell LineChlorocebus aethiopsDisease Models, AnimalEbolavirusFemaleFerretsFiloviridaeFiloviridae InfectionsGlycoproteinsGuinea PigsHEK293 CellsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteinsViral ProteinsADI-15878ADI-23774BDBVBundibugyoebolavirusEBOVMBP134pan-ebolavirusSudanSUDV
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.